ProQR Therapeutics (PRQR) Total Non-Current Liabilities (2013 - 2026)

ProQR Therapeutics (PRQR) has reported Total Non-Current Liabilities for 14 consecutive years, with $30.0 million the latest figure, recorded in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 32.43% year-over-year to $30.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.0 million (down 32.43% YoY) and the FY2025 annual result came in at $35.2 million, down 23.59% from the prior year.
• Total Non-Current Liabilities fell to $30.0 million in Q1 2026 per PRQR's latest filing, from $35.2 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for PRQR reached as high as $95.2 million in Q4 2022 and fell as low as $30.0 million in Q1 2026.
• A 5-year average of $50.1 million and a median of $44.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities increased 21.67% — and 2024, when it plunged 34.99%.
• Year by year, Total Non-Current Liabilities stood at $95.2 million in 2022, then retreated by 25.54% to $70.9 million in 2023, then tumbled by 34.99% to $46.1 million in 2024, then slipped by 23.59% to $35.2 million in 2025, then fell by 14.75% to $30.0 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $30.0 million, $35.2 million, and $38.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.